CADTH Canadian Drug Expert Committee recommendation : Nitisinone (nitisinone tablets - Cycle Pharmaceuticals Ltd.) : indication : the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

Common drug review clinical review report.

Common drug review clinical review report

Language:

English

Subjects (All):

Drugs--Cost effectiveness.

Drugs.

Physical Description:

1 online resource.

Edition:

First edition.

Place of Publication:

Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2018.

Summary:

The CADTH Canadian Drug Expert Committee (CDEC) recommends that nitisinone (MDK-Nitisinone) be reimbursed for the treatment of adult and pediatric patients with HT-1 in combination with dietary restriction of tyrosine and phenylalanine, if the following criterion and conditions are met: for use in patients with an established diagnosis of HT-1. The drug is prescribed by a physician with experience in the diagnosis and management of HT-1. The total cost of treatment with nitisinone (MDK-Nitisinone) should not exceed the drug plan cost of other nitisinone products.

Notes:

Description based on publisher supplied metadata and other sources.